|  |  |
| --- | --- |
| **Inclusion Criteria** | **Exclusion Criteria** |
| * Patient (male , female) 45 years or older and have at least one of the following risk factors of disease degradation described by the French High Council of Public Health:
	+ ≥70 years old,
	+ BMI > 30,
	+ cardiovascular history (stroke, coronary artery disease, complicated hypertension, cardiac surgery, NYHA III or IV heart failure),
	+ insulin-dependent diabetes which is unbalanced or secondary complicated,
	+ respiratory disease likely to decompensate for viral infection,
	+ patients with chronic renal failure on dialysis,
	+ cancer patients under treatment
* Patient must have signed an informed consent.
* Symptomatic patient, having at least one of the following symptoms without hospitalisation criteria:
* General symptoms: fever, headache, asthenia
* ENT symptoms: sore throat, rhinorrhea
* Respiratory symptoms: dyspnoea, breathing rate > 22/min,
* Digestive symptoms: nausea, vomiting, diarrhea
* Patient with social security .
 | * Patient with a lactose intolerance.
* Patient with a condition requiring immediate hospitalization whatever the medical reason.
* Patient with more than 5 days of clinical disorders at inclusion visit.
* Patient with an history of allergy to tetracyclin.
* Pregnant or nursing women.
* Patient enrolled in another clinical trial.
* Patient with a photosensitive cutaneous disease.
* Patient treated with oral anticoagulant therapies.
* Patient treated with oral retinoids : isotretinoin, alotretinoin, acitretin.
* Patient treated with vitamin A.
* Patient treated with a systemic antibiotherapy during treatment duration.
* Patient treated with barbiturates, carbamazepine or phenytoin.
* Patient with traitement that may have an effect on SARS-CoV2 infection : chloroquin, hydroxychloroquin, remdesivir, ganciclovir, acyclovir, ribavirin, lopinavir/ritonavir
* Adults under legal protection
 |